日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

更正：一项多中心临床研究，旨在评估免疫球蛋白皮下注射20%（每周/每两周一次）在经治疗患者中的药代动力学、疗效和安全性，以及在初治原发性免疫缺陷患者中的负荷剂量/每周维持剂量。

期刊:Journal of Clinical Immunology
影响因子:5.7
doi:10.1007/s10875-026-01983-6
Lumry, William R; Palumbo, Michael; Hsu, Connie; Hussain, Iftikhar; McNeil, Donald; Bridges, Tracy; Wedner, H James; Scarupa, Mark; Mondou, Elsa; Nanaware-Kharade, Nisha; Hanna, Kim; Coll, Montse Querolt; Oliveras, Juan
免疫/内分泌
发表日期：2026
文献求助 收藏

An International Delphi Study on Barriers to On-Demand Treatment of Hereditary Angioedema Attacks

一项关于按需治疗遗传性血管性水肿发作障碍的国际德尔菲研究

期刊:Clinical and Translational Allergy
影响因子:4
doi:10.1002/clt2.70159
Banerji, Aleena; Aygören-Pürsün, Emel; Bara, Noemi-Anna; Bernstein, Jonathan A; Betschel, Stephen; Bouillet, Laurence; Busse, Paula J; Caballero, Teresa; Cancian, Mauro; Cohn, Danny M; Craig, Timothy; Farkas, Henriette; Grumach, Anete Sevciovic; Hide, Michihiro; Kiani-Alikhan, Sorena; Longhurst, Hilary J; Lumry, William R; Riedl, Marc A; Stobiecki, Marcin; Valerieva, Anna; Zanichelli, Andrea
发表日期：2026
文献求助 收藏

Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1

多尼达洛森用于遗传性血管性水肿发作的长期预防：OASISplus开放标签扩展队列第1年的结果

期刊:Journal of Asthma and Allergy
影响因子:3
doi:10.2147/JAA.S592079
Lumry, William R; Tachdjian, Raffi; Craig, Timothy; Karakaya, Gül; Gelincik, Asli; Stobiecki, Marcin; Jacobs, Joshua S; Gokmen, Nihal Mete; Reshef, Avner; Manning, Michael E; Grammatikos, Alexandros; Giardino, Francesco; Guilarte, Mar; Baptist, Alan P; Bordone, Laura; Newman, Kenneth B; Treadwell, Sabrina; Lin, Tao; Yarlas, Aaron; Riedl, Marc A; Cohn, Danny M
发表日期：2026
文献求助 收藏

Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world

真实世界中，美国遗传性血管性水肿患者接受贝罗曲司他治疗后，血管性水肿发作率降低

期刊:Allergy Asthma and Clinical Immunology
影响因子:2.4
doi:10.1186/s13223-025-01005-x
Davis-Lorton, Mark; Tachdjian, Raffi; Lopez-Gonzalez, Lorena; MacKnight, Sean D; Ramasubramanian, Ramya; Laliberté, François; Gillard, Patrick; LiVecchi, Meri; Nestler-Parr, Sandra; Lumry, William R
发表日期：2026
文献求助 收藏

Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years

接受 Lanadelumab 治疗 3 年或以上的遗传性血管性水肿患者的长期真实世界结果

期刊:International Archives of Allergy and Immunology
影响因子:1.8
doi:10.1159/000546987
Lumry, William R; Davis-Lorton, Mark; Soteres, Daniel; Earl, Lucy; Wynne-Cattanach, Kieran; Fox, Daniel; Sing, Krystal; Juethner, Salomé; Schultz, Bob G
发表日期：2026
文献求助 收藏

Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis

接受拉那德鲁单抗或其他长期预防治疗的遗传性血管性水肿患者的真实世界生活质量

期刊:Allergy and Asthma Proceedings
影响因子:
doi:10.2500/aap.2026.47.250104
Davis-Lorton, Mark; Soteres, Daniel; Lumry, William R; Hall, Jennifer; Connolly, Hannah; Fox, Daniel; Sing, Krystal; Schultz, Bob G; Juethner, Salomé
发表日期：2026
文献求助 收藏

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

一项多中心临床研究，旨在评估免疫球蛋白皮下注射20%（每周/每两周一次）在经治疗患者中的药代动力学、疗效和安全性，以及在初治原发性免疫缺陷患者中负荷剂量/每周维持剂量的疗效。

期刊:Journal of Clinical Immunology
影响因子:5.7
doi:10.1007/s10875-025-01952-5
Lumry, William R; Palumbo, Michael; Hsu, Connie; Hussain, Iftikhar; McNeil, Donald; Bridges, Tracy; Wedner, H James; Scarupa, Mark; Mondou, Elsa; Nanaware-Kharade, Nisha; Hanna, Kim; Coll, Montse Querolt; Oliveras, Juan
免疫/内分泌
发表日期：2025
文献求助 收藏

Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study

Lanadelumab 长期预防治疗遗传性血管性水肿的持续有效性、耐受性和安全性：前瞻性、4 期、非干预性 EMPOWER 真实世界研究

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03226-3
Bernstein, Jonathan A; Betschel, Stephen D; Busse, Paula J; Banerji, Aleena; Wedner, H James; Manning, Michael; Zaragoza-Urdaz, Rafael H; Anderson, John; Gagnon, Remi; Baptist, Alan P; Soteres, Daniel; Lumry, William R; Craig, Timothy; Petroni, Daniel; Hsu, F Ida; Nova Estepan, Daniel; Juethner, Salomé; Watt, Maureen; Khutoryansky, Natalie; Zuraw, Bruce L
发表日期：2025
文献求助 收藏

Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S

KONFIDENT-S 研究中，Sebetralstat 用于按需治疗粘膜遗传性血管性水肿发作。

期刊:Clinical and Translational Allergy
影响因子:4
doi:10.1002/clt2.70118
Bernstein, Jonathan A; Aygören-Pürsün, Emel; Cancian, Mauro; Cohn, Danny M; Craig, Timothy; Grivcheva-Panovska, Vesna; Jordan, Anthony; Lumry, William R; Martinez-Saguer, Inmaculada; Melamed, Isaac; Ohmura, Kazumasa; Peter, Jonny; Riedl, Marc A; Soteres, Daniel F; Staubach, Petra; Stobiecki, Marcin; Chuang, Ya-Hsiu; Smith, Michael D; Yea, Christopher M; Audhya, Paul K; Zanichelli, Andrea; Farkas, Henriette
IDE
发表日期：2025
文献求助 收藏

Barriers and promoters to adapting research findings to clinical care in hereditary angioedema in the United States: A qualitative study

美国遗传性血管性水肿研究成果应用于临床治疗的障碍和促进因素：一项定性研究

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0329585
Langmack, Esther L; Ravyn, Dana; Lowney, Rob; Goodwin, Beth; Lumry, William R
发表日期：2025
文献求助 收藏